Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.  

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

Engineered antibodies trap and immobilize human sperm in the reproductive tract of female sheep, paving the way for possible use as a nonhormonal contraceptive in people.

When researchers injected mice with antibodies from fibromyalgia patients, the animals developed symptoms of the disease—suggesting that it may be controlled by the immune system, not the nervous system.

More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.  

This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.

Scientists are on the hunt for a shot that will protect against not only SARS-CoV-2, but other members of its family that may emerge in the future.

Researchers at Imperial College London and the University of Oxford are exposing healthy volunteers to SARS-CoV-2 for science.

Some of the blood specimens collected in the United States for the NIH’s All of Us research program starting on January 2, 2020, have antibodies against SARS-CoV-2.

By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.